title: Nanomedicine and the complement paradigm.
abstract: The role of complement in idiosyncratic reactions to nanopharmaceutical infusion is receiving increasing attention. We discuss this in relation to nanopharmaceutical development and the possible use of complement inhibitors to prevent related adverse reactions. We further call on initiation of genetic association studies to unravel the genetic basis of nanomedicine infusion-related adverse responses, since most of the polymorphic genes in the genome belong to the immune system.
  
  
  BACKGROUND
  In this paper, idiosyncratic reactions based on complement activation are discussed in the context of newly available complement inhibitors.
authors.affiliation: Nanomedicine Research Group, Centre for Pharmaceutical Nanotechnology and Nanotoxicology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen Ø, Denmark. moien.moghimi@sund.ku.dk
authors.forename: S Moein
authors.initials: SM
authors.lastname: Moghimi
authors.forename: Z Shadi
authors.initials: ZS
authors.lastname: Farhangrazi
mesh_terms: D051056:Complement Inactivating Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D003165:Complement System Proteins / Q000502:physiology*; D050997:Nanomedicine
chemical_list: D051056:Complement Inactivating Agents; D003165:Complement System Proteins